Cerebral Venous Sinus Thrombosis in Women: Subgroup Analysis of the VENOST Study
Author(s) -
Derya Uludüz,
Şevki Şahin,
Taşkın Duman,
Şerefnur Öztürk,
Vildan Yayla,
Nazire Afşar,
Nevzat Üzüner,
İpek Midi,
Nilgün Çınar,
Mehmet Alı Sungur,
Füsun Mayda Domaç,
Birsen İnce,
Baki Göksan,
Cemile Handan Mısırlı,
Mustafa Bakar,
Hasan Hüseyin Kozak,
Sena Çolakoğlu,
Ali Yavuz Karahan,
Eylem Özaydın Göksu,
Fatih Özdağ,
Mehmet Güney Şenol,
Vedat Ali Yürekli,
Ufuk Aluçlu,
Serkan Demir,
Hayriye Küçükoğlu,
Serdar Oruç,
Nilüfer Yeşilot,
Ozge Yimaz Kusbeci,
Bijen Nazlıel,
Firdevs Ezgi Uçan Tokuç,
Hesna Bektaş,
Nida Taşçılar,
Emrah Aytaç,
Mustafa Gökçe,
Hale Zeynep Batur Çağlayan,
Ahmet Tüfekçi,
Dilek Neci̇oğlu Örken,
Osman Özgür Yalın,
Uygar Utku,
Arda Yılmaz,
Hamit Genç,
Murat Çabalar,
Aysel Milanlıoğlu,
Hakan Ekmekçi,
Burcu Zeydan,
Sevim Baybaş,
Yüksel Kablan,
Başak Karakurum Göksel,
Mustafa Açıkgöz,
Hatice Kurucu,
Seden Demirci,
Taşkın Güneş
Publication year - 2020
Publication title -
stroke research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.939
H-Index - 34
eISSN - 2090-8105
pISSN - 2042-0056
DOI - 10.1155/2020/8610903
Subject(s) - medicine , pregnancy , venous thrombosis , cerebral venous sinus thrombosis , subgroup analysis , thrombosis , pediatrics , obstetrics , group b , surgery , biology , confidence interval , genetics
Background Early diagnosis of cerebral venous sinus thrombosis (CVST) associated with reproductive health-related risk factors (RHRF) including pregnancy, puerperium, and oral contraceptive (OC) use can prevent severe neurological sequelae; thus, the symptoms must be documented in detail for each group.Methods Out of 1144 patients with CVST, a total of 777 women were enrolled from a multicenter for the study of cerebral venous sinus thrombosis (VENOST). Demographic, biochemical, clinical, and radiological aspects were compared for 324 cases with RHRF and 453 cases without RHRF.Results The mean age of the RHRF (-) group (43.2 ± 13 years) was significantly higher than of the RHRF (+) group (34 ± 9 years). A previous history of deep venous thrombosis (3%), isolated cavernous sinus involvement (1%), cranial neuropathy (13%), comorbid malignancy (7%), and its disability scores after 12 months (9%) were significantly higher in the RHRF (-) group. The RHRF (+) group consisted of 44% cases of puerperium, 33% cases of OC users and 23% of pregnant women. The mean age was found to be higher in OC users (38 ± 9 years). A previous history of deep venous thrombosis was slightly higher in the pregnancy subgroup (4%). Epileptic seizures were more common in the puerperium group (44%).Conclusion The results of our study indicate that the risk of CSVT increases parallel to age, OC use, and puerperium period. In addition, when considering the frequency of findings and symptoms, epileptic seizures in the puerperium subgroup of the RHRF (+) group and malignancies in the RHRF (-) group may accompany the CSVT. In daily practice, predicting these risks for the CSVT and early recognition of the symptoms will provide significant benefits to patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom